U.S. Pharmaceuticals & Biotech Most Popular Stocks

Alvotech

Market Cap: US$2.7b

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

Kiniksa Pharmaceuticals International

Market Cap: US$2.7b

A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.

Supernus Pharmaceuticals

Market Cap: US$2.6b

A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.

Amicus Therapeutics

Market Cap: US$2.6b

A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.

Veracyte

Market Cap: US$2.6b

Operates as a diagnostics company in the United States and internationally.

Bausch Health Companies

Market Cap: US$2.5b

Operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally.

Catalyst Pharmaceuticals

Market Cap: US$2.4b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

ImmunityBio

Market Cap: US$2.4b

A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.

Tarsus Pharmaceuticals

Market Cap: US$2.3b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Beam Therapeutics

Market Cap: US$2.3b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

Belite Bio

Market Cap: US$2.3b

A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.

Celcuity

Market Cap: US$2.3b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Apogee Therapeutics

Market Cap: US$2.3b

A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.

IDEAYA Biosciences

Market Cap: US$2.2b

A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Cidara Therapeutics

Market Cap: US$2.2b

Operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases.

Ocular Therapeutix

Market Cap: US$2.2b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

89bio

Market Cap: US$2.2b

A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.

Travere Therapeutics

Market Cap: US$2.2b

A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

Disc Medicine

Market Cap: US$2.2b

A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.

Agios Pharmaceuticals

Market Cap: US$2.2b

A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Recursion Pharmaceuticals

Market Cap: US$2.1b

Operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States.

Arcutis Biotherapeutics

Market Cap: US$2.1b

A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Adaptive Biotechnologies

Market Cap: US$2.0b

A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

BGM Group

Market Cap: US$2.0b

Through its subsidiaries, operates as a pharmaceutical and chemical company in China.

Denali Therapeutics

Market Cap: US$2.0b

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

ANI Pharmaceuticals

Market Cap: US$1.9b

A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

Intellia Therapeutics

Market Cap: US$1.9b

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

Liquidia

Market Cap: US$1.9b

A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

Dyne Therapeutics

Market Cap: US$1.9b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Cogent Biosciences

Market Cap: US$1.9b

A biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Harrow

Market Cap: US$1.8b

An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.

Pharvaris

Market Cap: US$1.8b

A late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.

Edgewise Therapeutics

Market Cap: US$1.7b

A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Sarepta Therapeutics

Market Cap: US$1.7b

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

Immunocore Holdings

Market Cap: US$1.7b

A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

Celldex Therapeutics

Market Cap: US$1.7b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.